GNPXGenprex, Inc.

Nasdaq genprex.com


$ 2.44 $ 0.08 (3.39 %)    

Friday, 03-May-2024 13:41:30 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 2.44
$ 2.52
$ 2.37 x 100
$ 0.00 x 0
$ 2.44 - $ 2.52
$ 2.09 - $ 42.40
23,002
na
4.66M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-21-2023 06-30-2023 10-Q
4 05-22-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-26-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 04-17-2018 12-31-2017 10-K
26 11-27-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genprex-earlier-reported-preclinical-data-for-reqorsa-immunogene-therapy-and-nprl2-gene-therapy-for-lung-cancer

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer T...

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 genprex-expands-clinical-trial-sites-for-acclaim-3-clinical-study-of-reqorsa-therapy-in-combination-with-tecentriq-for-small-cell-lung-cancer

 Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices       ...

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 genprex-publishes-preclinical-data-with-nprl2-gene-therapy-using-oncoprex-delivery-system

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanize...

 hc-wainwright--co-initiates-coverage-on-genprex-with-buy-rating-announces-price-target-of-10

HC Wainwright & Co. analyst Yi Chen initiates coverage on Genprex (NASDAQ:GNPX) with a Buy rating and announces Price Ta...

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 genprex-collaborators-to-present-preclinical-data-on-use-of-reqorsa-and-on-nprl2-gene-therapy-utilizing-non-viral-oncoprex-delivery-system-for-lung-cancers-at-2024-aacr-annual-meeting

Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung CancerREQORSA has Anti-Tumor Mechanisms that Targe...

 genprex-expands-nonclinical-programs-through-sponsored-research-agreements-and-material-transfer-agreements-to-study-tusc2-and-nprl2-tumor-suppressor-genes

Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung CancerThree Collaborators Selected to Present Positive Noncli...

 dow-turns-lower-federal-reserve-keeps-rates-unchanged

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1.5% on Wednesday. The Dow traded...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

 crude-oil-down-2-alphabet-shares-fall-after-q4-results

U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION